We are live on ! Find out more
NWBO

Northwest Biotherapeutics, Inc. Common stock
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

Back to rankings

4 hedge funds and large institutions have $10K invested in Northwest Biotherapeutics, Inc. Common stock in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

150% more capital invested

Capital invested by funds: $4K → $10K (+$6K)

100% more funds holding

Funds holding: 2 → 4 (+2)

Holders
4
Holders Change
+2
Holders Change %
+100%
% of All Funds
0.1%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
LDB
Lee, Danner & Bass
Tennessee
+$4K
2
WPP
Whalerock Point Partners
Rhode Island
+$4K

Top Sellers

Rank Fund Capital Flow
1
GT
Glenmede Trust
Pennsylvania
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
LDB
1
Lee, Danner & Bass
Tennessee
$4K +$4K +20,000 New
WPP
2
Whalerock Point Partners
Rhode Island
$4K +$4K +20,000 New
MPI
3
Mairs & Power Inc
Minnesota
$2K – – –
GT
4
Glenmede Trust
Pennsylvania
– -$2K -12,150 Closed

NWBO Hedge Fund Activity: Q3 2017 in Review

4 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q3 2017, worth a combined $10K — up 150% from $4K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new NWBO positions and 1 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Lee, Danner & Bass, opening a new position worth an estimated $4K. The largest seller was Glenmede Trust, exiting entirely with an estimated $2K sold.

  • 4 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q3 2017, up from 2 in Q2 2017.
  • Funds reported $10K of Northwest Biotherapeutics, Inc. Common stock stock for Q3 2017, up 150% quarter-over-quarter.
  • 3 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q3 2017 and 1 closed out, a net change of +2 holders.
  • The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q3 2017 was Lee, Danner & Bass, an estimated $4K added.
  • The largest Northwest Biotherapeutics, Inc. Common stock seller in Q3 2017 was Glenmede Trust, an estimated $2K sold.

Based on aggregated 13F filings for Q3 2017.